Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697727 | 0.79 | TP53 (0.42) | SLC6A4POLB | |
| SCHEMBL5169008 | 0.75 | MEN1 (0.51) | MEN1MAPK1KMT2AOPRM1OPRD1 | |
| SCHEMBL1811353 | 0.74 | MEN1 (0.50) | MEN1MAPK1KMT2AOPRM1OPRD1 | |
| SCHEMBL22869165 | 0.74 | MEN1 (0.70) | MEN1MAPK1KMT2AOPRM1OPRD1 | |
| SCHEMBL21761027 | 0.73 | OPRM1 (0.39) | MEN1MAPK1KMT2AOPRM1OPRD1 | |
| SCHEMBL14709959 | 0.72 | OPRM1 (0.39) | MEN1MAPK1KMT2AOPRM1OPRD1 | |
| SCHEMBL19814664 | 0.72 | CNR2 (0.38) | POLB | |
| SCHEMBL24618311 | 0.71 | MEN1 (0.48) | MEN1MAPK1KMT2AOPRM1OPRD1 | |
| SCHEMBL23972752 | 0.71 | SMN1; SMN2 (0.38) | MAPK1KMT2ASLC6A4 | |
| SCHEMBL24618312 | 0.71 | MEN1 (0.47) | MEN1MAPK1KMT2AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| CN-102405211-A | Proline derivatives as cathepsin inhibitors | HOFFMANN LA ROCHE | 2012-04-04 | — | — | CN | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | MEN1 2996/4885MAPK1 1675/4885KMT2A 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.